Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression

Progress in Neurobiology

Volumn 95, Issue 4, 2011, Pages 547-556

  Teipel, Stefan J ^a,b   Buchert, Ralph ^c   Thome, Johannes ^a   Hampel, Harald ^d   Pahnke, Jens ^a,b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

Alzheimer disease; Amyloid pathology; Molecular imaging; PET; Transgenic models; Ultra highfield MRI

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; BRAIN ATROPHY; DEMENTIA; HISTOPATHOLOGY; MILD COGNITIVE IMPAIRMENT; NEUROBIOLOGY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TRANSGENE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BIOLOGICAL MARKERS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; NEUROIMAGING; PLAQUE, AMYLOID;

EID: 82755193805     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.05.004     Document Type: Review

References (104)

1. Beekman F., van der Have F. The pinhole: gateway to ultra-high-resolution three-dimensional radionuclide imaging. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:151-161.
2. Benveniste H., Einstein G., Kim K.R., Hulette C., Johnson G.A. Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:14079-14084.
3. Benveniste H., Ma Y., Dhawan J., Gifford A., Smith S.D., Feinstein I., Du C., Grant S.C., Hof P.R. Anatomical and functional phenotyping of mice models of Alzheimer's disease by MR microscopy. Ann. N.Y. Acad. Sci. 2007, 1097:12-29.
4. Bianca V.D., Dusi S., Bianchini E., Dal Pra I., Rossi F. Beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. J. Biol. Chem. 1999, 274:15493-15499.
5. Biomarkers_Definitions_Working_Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95.
6. Bobinski M., de Leon M.J., Wegiel J., Desanti S., Convit A., Saint Louis L.A., Rusinek H., Wisniewski H.M. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 2000, 95:721-725.
7. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., Slunt H.H., Wang R., Seeger M., Levey A.I., Gandy S.E., Copeland N.G., Jenkins N.A., Price D.L., Younkin S.G., Sisodia S.S. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17:1005-1013.
8. Borg J., Chereul E. Differential MRI patterns of brain atrophy in double or single transgenic mice for APP and/or SOD. J. Neurosci. Res. 2008, 86:3275-3284.
9. Braakman N., Matysik J., van Duinen S.G., Verbeek F., Schliebs R., de Groot H.J., Alia A. Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J. Magn. Reson. Imaging 2006, 24:530-536.
10. Branderhorst W., Vastenhouw B., van der Have F., Blezer E.L., Bleeker W.K., Beekman F.J. Targeted multi-pinhole SPECT. Eur. J. Nucl. Med. Mol. Imaging. 2011, 38:552-561.
11. Cai L., Chin F.T., Pike V.W., Toyama H., Liow J.S., Zoghbi S.S., Modell K., Briard E., Shetty H.U., Sinclair K., Donohue S., Tipre D., Kung M.P., Dagostin C., Widdowson D.A., Green M., Gao W., Herman M.M., Ichise M., Innis R.B. Synthesis and evaluation of two 18F-labeled 6-iodo-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for beta-amyloid in Alzheimer's disease. J. Med. Chem. 2004, 47:2208-2218.
12. Cai L., Liow J.S., Zoghbi S.S., Cuevas J., Baetas C., Hong J., Shetty H.U., Seneca N.M., Brown A.K., Gladding R., Temme S.S., Herman M.M., Innis R.B., Pike V.W. Synthesis and evaluation of N-methyl and S-methyl 11C-labeled 6-methylthio-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridines as radioligands for imaging beta-amyloid plaques in Alzheimer's disease. J. Med. Chem. 2008, 51:148-158.
13. Carpenter A.P., Pontecorvo M.J., Hefti F.F., Skovronsky D.M. The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience. Q. J. Nucl. Med. Mol. Imaging 2009, 53:387-393.
14. Cheng I.H., Palop J.J., Esposito L.A., Bien-Ly N., Yan F., Mucke L. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat. Med. 2004, 10:1190-1192.
15. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P.S., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 2001, 276:21562-21570.
16. Choi S.R., Golding G., Zhuang Z., Zhang W., Lim N., Hefti F., Benedum T.E., Kilbourn M.R., Skovronsky D., Kung H.F. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J. Nucl. Med. 2009, 50:1887-1894.
17. Dedeoglu A., Choi J.K., Cormier K., Kowall N.W., Jenkins B.G. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 2004, 1012:60-65.
18. Delatour B., Guegan M., Volk A., Dhenain M. In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice. Neurobiol. Aging 2006, 27:835-847.
19. Duan X.H., Qiao J.P., Yang Y., Cui M.C., Zhou J.N., Liu B.L. Novel anilinophthalimide derivatives as potential probes for beta-amyloid plaque in the brain. Bioorg. Med. Chem. 2010, 18:1337-1343.
20. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
21. Dubois B., Picard G., Sarazin M. Early detection of Alzheimer's disease: new diagnostic criteria. Dial. Clin. Neurosci. 2009, 11:135-139.
22. Faber C., Zahneisen B., Tippmann F., Schroeder A., Fahrenholz F. Gradient-echo and CRAZED imaging for minute detection of Alzheimer plaques in an APPV717I×ADAM10-dn mouse model. Magn. Reson. Med. 2007, 57:696-703.
23. Falangola M.F., Ardekani B.A., Lee S.P., Babb J.S., Bogart A., Dyakin V.V., Nixon R., Duff K., Helpern J.A. Application of a non-linear image registration algorithm to quantitative analysis of T2 relaxation time in transgenic mouse models of AD pathology. J. Neurosci. Methods 2005, 144:91-97.
24. Fodero-Tavoletti M.T., Villemagne V.L., Paterson B.M., White A.R., Li Q.X., Camakaris J., O'Keefe G., Cappai R., Barnham K.J., Donnelly P.S. Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease. J. Alzheimers Dis. 2010, 20:49-55.
25. Fox G.B., Chin C.L., Luo F., Day M., Cox B.F. Translational neuroimaging of the CNS: novel pathways to drug development. Mol. Interv. 2009, 9:302-313.
26. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
27. Hampel H., Frank R., Broich K., Teipel S.J., Katz R.G., Hardy J., Herholz K., Bokde A.L., Jessen F., Hoessler Y.C., Sanhai W.R., Zetterberg H., Woodcock J., Blennow K. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. 2010, 9:560-574.
28. Hampel H., Wilcock G., Andrieu S., Aisen P., Blennow K., Broich K., Carrillo M., Fox N.C., Frisoni G.B., Isaac M., Lovestone S., Nordberg A., Prvulovic D., Sampaio C., Scheltens P., Weiner M., Winblad B., Coley N., Vellas B. Biomarkers for Alzheimer's disease therapeutic trials. Prog. Neurobiol. 2011.
29. Hardy J. The shorter amyloid cascade hypothesis. Neurobiol. Aging 1999, 20:85. discussion 87.
30. Hardy J. Testing times for the "amyloid cascade hypothesis". Neurobiol. Aging 2002, 23:1073-1074.
31. Hardy J.A., Mann D.M., Wester P., Winblad B. An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease. Neurobiol. Aging 1986, 7:489-502.
32. Helpern J.A., Jensen J., Lee S.P., Falangola M.F. Quantitative MRI assessment of Alzheimer's disease. J. Mol. Neurosci. 2004, 24:45-48.
33. Herzig M.C., Winkler D.T., Burgermeister P., Pfeifer M., Kohler E., Schmidt S.D., Danner S., Abramowski D., Sturchler-Pierrat C., Burki K., van Duinen S.G., Maat-Schieman M.L., Staufenbiel M., Mathews P.M., Jucker M. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci. 2004, 7:954-960.
34. Higuchi M. Visualization of brain amyloid and microglial activation in mouse models of Alzheimer's disease. Curr. Alzheimers Res. 2009, 6:137-143.
35. Higuchi M., Maeda J., Ji B., Maruyama M., Okauchi T., Tokunaga M., Ono M., Suhara T. In vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: insights from neuroimaging research in humans and rodent models. Biochim. Biophys. Acta 2011, 1802:373-388.
36. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 1998, 4:97-100.
37. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
38. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (New York, N.Y.) 1996, 274:99-102.
39. Irizarry M.C., Soriano F., McNamara M., Page K.J., Schenk D., Games D., Hyman B.T. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 1997, 17:7053-7059.
40. Jack C.R., Garwood M., Wengenack T.M., Borowski B., Curran G.L., Lin J., Adriany G., Grohn O.H., Grimm R., Poduslo J.F. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn. Reson. Med. 2004, 52:1263-1271.
41. Jack C.R., Wengenack T.M., Reyes D.A., Garwood M., Curran G.L., Borowski B.J., Lin J., Preboske G.M., Holasek S.S., Adriany G., Poduslo J.F. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J. Neurosci. 2005, 25:10041-10048.
42. Jessen F., Traeber F., Freymann K., Maier W., Schild H.H., Block W. Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 2006, 67:528-530.
43. Jones R.S., Waldman A.D. 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. Neurol. Res. 2004, 26:488-495.
44. Junck L., Olson J.M., Ciliax B.J., Koeppe R.A., Watkins G.L., Jewett D.M., McKeever P.E., Wieland D.M., Kilbourn M.R., Starosta-Rubinstein S., et al. PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann. Neurol. 1989, 26:752-758.
45. Kantarci K. 1H magnetic resonance spectroscopy in dementia. Br. J. Radiol. 2007, 80(Spec No 2):S146-S152.
46. Kemp B.J., Hruska C.B., McFarland A.R., Lenox M.W., Lowe V.J. NEMA NU 2-2007 performance measurements of the Siemens Inveon preclinical small animal PET system. Phys. Med. Biol. 2009, 54:2359-2376.
47. Kessler R.M., Ellis J.R., Eden M. Analysis of emission tomographic scan data: limitations imposed by resolution and background. J. Comput. Assist. Tomogr. 1984, 8:514-522.
48. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
49. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
50. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., Debnath M.L., Holt D.P., Huang G.F., Shao L., DeKosky S.T., Price J.C., Mathis C.A. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 2005, 25:10598-10606.
51. Klunk W.E., Mathis C.A. The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr. Opin. Neurol. 2008, 21:683-687.
52. Kung M.P., Hou C., Zhuang Z.P., Zhang B., Skovronsky D., Trojanowski J.Q., Lee V.M., Kung H.F. IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res. 2002, 956:202-210.
53. Lau J.C., Lerch J.P., Sled J.G., Henkelman R.M., Evans A.C., Bedell B.J. Longitudinal neuroanatomical changes determined by deformation-based morphometry in a mouse model of Alzheimer's disease. Neuroimage 2008, 42:19-27.
54. Lockhart A., Lamb J.R., Osredkar T., Sue L.I., Joyce J.N., Ye L., Libri V., Leppert D., Beach T.G. PIB is a non-specific imaging marker of amyloid-beta (A{beta}) peptide-related cerebral amyloidosis. Brain 2007, 130:2607-2615.
55. Ma Y., Hof P.R., Grant S.C., Blackband S.J., Bennett R., Slatest L., McGuigan M.D., Benveniste H. A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy. Neuroscience 2005, 135:1203-1215.
56. Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., Staufenbiel M., Iwata N., Ono M., Saido T.C., Suzuki K., Mori H., Higuchi M., Suhara T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 2007, 27:10957-10968.
57. Marcucci F., Airoldi L., Mussini E. Brain level of N-acetyl-l-aspartate in different strains of mouse and rat. J. Neurochem. 1969, 16:272-273.
58. Marjanska M., Curran G.L., Wengenack T.M., Henry P.G., Bliss R.L., Poduslo J.F., Jack C.R., Ugurbil K., Garwood M. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:11906-11910.
59. Massoud T.F., Gambhir S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003, 17:545-580.
60. Mathis C.A., Wang Y., Holt D.P., Huang G.F., Debnath M.L., Klunk W.E. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 2003, 46:2740-2754.
61. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
62. Meadowcroft M.D., Connor J.R., Smith M.B., Yang Q.X. MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice. J. Magn. Reson. Imaging 2009, 29:997-1007.
63. Meltzer C.C., Zubieta J.K., Brandt J., Tune L.E., Mayberg H.S., Frost J.J. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 1996, 47:454-461.
64. Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., Kuhl D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 1997, 42:85-94.
65. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
66. Nakada T., Matsuzawa H., Igarashi H., Fujii Y., Kwee I.L. In vivo visualization of senile-plaque-like pathology in Alzheimer's disease patients by MR microscopy on a 7T system. J. Neuroimaging 2008, 18:125-129.
67. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006, 26:10129-10140.
68. Oberg J., Spenger C., Wang F.H., Andersson A., Westman E., Skoglund P., Sunnemark D., Norinder U., Klason T., Wahlund L.O., Lindberg M. Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice. Neurobiol. Aging 2008, 29:1423-1433.
69. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 2003, 24:1063-1070.
70. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
71. Pahnke J., Walker L.C., Scheffler K., Krohn M. Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression?. Neurosci. Biobehav. Rev. 2009, 33:1099-1108.
72. Penner J., Rupsingh R., Smith M., Wells J.L., Borrie M.J., Bartha R. Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:104-110.
73. Phelps M.E. PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med. 2000, 41:661-681.
74. Poduslo J.F., Wengenack T.M., Curran G.L., Wisniewski T., Sigurdsson E.M., Macura S.I., Borowski B.J., Jack C.R. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol. Dis. 2002, 11:315-329.
75. Rabinovici G.D., Jagust W.J. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav. Neurol. 2009, 21:117-128.
76. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jaggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Holscher C., Mathews P.M., Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006, 7:940-946.
77. Ramsden M., Kotilinek L., Forster C., Paulson J., McGowan E., SantaCruz K., Guimaraes A., Yue M., Lewis J., Carlson G., Hutton M., Ashe K.H. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J. Neurosci. 2005, 25:10637-10647.
78. Redwine J.M., Kosofsky B., Jacobs R.E., Games D., Reilly J.F., Morrison J.H., Young W.G., Bloom F.E. Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1381-1386.
79. Reiman E.M., Uecker A., Gonzalez-Lima F., Minear D., Chen K., Callaway N.L., Berndt J.D., Games D. Tracking Alzheimer's disease in transgenic mice using fluorodeoxyglucose autoradiography. Neuroreport 2000, 11:987-991.
80. Riemann B., Schafers K.P., Schober O., Schafers M. Small animal PET in preclinical studies: opportunities and challenges. Q. J. Nucl. Med. Mol. Imaging 2008, 52:215-221.
81. Rosen R.F., Walker L.C., Levine H. PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease. Neurobiol. Aging 2011, 32:223-234.
82. Rowland D.J., Cherry S.R. Small-animal preclinical nuclear medicine instrumentation and methodology. Semin. Nucl. Med. 2008, 38:209-222.
83. Scheffler, K., Stenzel, J., Krohn, M., Lange, C., Hofrichter, J., Schumacher, T., Brüning, T., Plath, A.-S., Walker, L., Pahnke, J., Determination of spatial and temporal distribution of microglia by 230nm-high-resolution, high-throughput automated analysis reveals different amyloid plaque populations in an APP/PS1 mouse model of Alzheimer's disease. Curr. Alzheimer Res., in press.
84. Serdons K., Van Laere K., Janssen P., Kung H.F., Bormans G., Verbruggen A. Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 2009, 52:7090-7102.
85. Sharma S., Ebadi M. SPECT neuroimaging in translational research of CNS disorders. Neurochem. Int. 2008, 52:352-362.
86. Shidahara M., Tsoumpas C., Hammers A., Boussion N., Visvikis D., Suhara T., Kanno I., Turkheimer F.E. Functional and structural synergy for resolution recovery and partial volume correction in brain PET. Neuroimage 2009, 44:340-348.
87. Spillantini M.G., Murrell J.R., Goedert M., Farlow M.R., Klug A., Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:7737-7741.
88. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:13287-13292.
89. Teipel S., Kaza E., Hadlich S., Brüning T., Plath A.-S., Scheffler K., Krohn M., Bauer A., Walker L., Lotze M., Pahnke J. Automated detection of beta-amyloid-related cortical and subcortical signal changes in a transgenic model of Alzheimer's disease using high-field MRI. J. Alzheimers Dis. 2011, E-pub ahead of print.
90. Teipel S.J., Meindl T., Grinberg L., Heinsen H., Hampel H. Novel MRI techniques in the assessment of dementia. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(Suppl 1):S58-69.
91. Toyama H., Ye D., Ichise M., Liow J.S., Cai L., Jacobowitz D., Musachio J.L., Hong J., Crescenzo M., Tipre D., Lu J.Q., Zoghbi S., Vines D.C., Seidel J., Katada K., Green M.V., Pike V.W., Cohen R.M., Innis R.B. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:593-600.
92. U.S. Department of Health and Human Services, F.a.D.A., Center for Drug Evaluation and Research, 2006. Guidance for Industry, Investigators, and Reviewers: Explanatory IND Studies.
93. Valla J., Chen K., Berndt J.D., Gonzalez-Lima F., Cherry S.R., Games D., Reiman E.M. Effects of image resolution on autoradiographic measurements of posterior cingulate activity in PDAPP mice: implications for functional brain imaging studies of transgenic mouse models of Alzheimer's disease. Neuroimage 2002, 16:1-6.
94. Vanhoutte G., Dewachter I., Borghgraef P., Van Leuven F., Van der Linden A. Non-invasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn. Reson. Med. 2005, 53:607-613.
95. Venneti S., Lopresti B.J., Wang G., Hamilton R.L., Mathis C.A., Klunk W.E., Pate U.M., Wiley C.A. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol. Aging 2009, 30:1217-1226.
96. von Kienlin M., Koneke B., Metzger F., Steiner G., Richards J.G., Ozmen L., Jacobsen H., Loetscher H. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol. Dis. 2005, 18:32-39.
97. Wengenack T.M., Curran G.L., Poduslo J.F. Targeting Alzheimer amyloid plaques in vivo. Nat. Biotechnol. 2000, 18:868-872.
98. Wengenack T.M., Reyes D.A., Curran G.L., Borowski B.J., Lin J., Preboske G.M., Holasek S.S., Gilles E.J., Chamberlain R., Marjanska M., Jack C.R., Garwood M., Poduslo J.F. Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain. Neuroimage 2011, 54:113-122.
99. Westman E., Spenger C., Oberg J., Reyer H., Pahnke J., Wahlund L.O. In vivo 1H-magnetic resonance spectroscopy can detect metabolic changes in APP/PS1 mice after donepezil treatment. BMC Neurosci. 2009, 10:33.
100. Wirths O., Breyhan H., Cynis H., Schilling S., Demuth H.U., Bayer T.A. Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol. 2009, 118:487-496.
101. Wong D.F., Tauscher J., Grunder G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 2009, 34:187-203.
102. Yang D., Xie Z., Stephenson D., Morton D., Hicks C.D., Brown T.M., Sriram R., O'Neill S., Raunig D., Bocan T. Volumetric MRI and MRS provide sensitive measures of Alzheimer's disease neuropathology in inducible Tau transgenic mice (rTg4510). Neuroimage 2011, 54:2652-2658.
103. Zhang, H., Bao, Q., Vu, N.T., Silverman, R.W., Taschereau, R., Berry-Pusey, B.N., Douraghy, A., Rannou, F.R., Stout, D.B., Chatziioannou, A.F., Performance evaluation of PETbox: a low cost bench top preclinical PET scanner. Mol. Imaging Biol., in press.
104. Zheng M.Q., Yin D.Z., Zhang L., Lei B., Cheng D.F., Cai H.C., Han Y.J., Wu M.X., Zhang H., Wang J. Biological characters of [18F]O-FEt-PIB in a rat model of Alzheimer's disease using micro-PET imaging. Acta Pharmacol. Sinica 2008, 29:548-554.